Cargando…
How Do Cancer-Related Mutations Affect the Oligomerisation State of the p53 Tetramerisation Domain?
Tumour suppressor p53 plays a key role in the development of cancer and has therefore been widely studied in recent decades. While it is well known that p53 is biologically active as a tetramer, the tetramerisation mechanism is still not completely understood. p53 is mutated in nearly 50% of cancers...
Autores principales: | Nicolini, Federica, Todorovski, Toni, Puig, Eduard, Díaz-Lobo, Mireia, Vilaseca, Marta, García, Jesús, Andreu, David, Giralt, Ernest |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296842/ https://www.ncbi.nlm.nih.gov/pubmed/37367066 http://dx.doi.org/10.3390/cimb45060317 |
Ejemplares similares
-
Protein–like fully reversible tetramerisation and super-association of an aminocellulose
por: Nikolajski, Melanie, et al.
Publicado: (2014) -
An Asymptomatic, Ectopic Mass as a Presentation of Adrenocortical Carcinoma Due to a Novel Germline TP53 p.Phe338Leu Tetramerisation Domain Variant
por: Walenciak, Justyna, et al.
Publicado: (2023) -
Implication of the Transmembrane Domain in the Interleukin 10 Receptor Platform Oligomerisation
por: Kuntzel, Thomas, et al.
Publicado: (2023) -
Algorithm-supported, mass and sequence diversity-oriented random peptide library design
por: Kalafatovic, Daniela, et al.
Publicado: (2019) -
DNA-bridging by an archaeal histone variant via a unique tetramerisation interface
por: Ofer, Sapir, et al.
Publicado: (2023)